A study to find out how long a person continues to have antibodies against Meningococcal B disease following vaccination To describe the immunogenicity of bivalent rLP2086 as determined by hSBA titers to primary test strains at approximately 6, 12, 18, 24, 36, and 48 months after the last dose (second or third dose) of ...

• Country None
• organs None
• Specialty None

A STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S) COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ADEQUATE RESPONSE WITH ETANERCEPT PLUS DMARD(S) VIZSGÁLAT AZ ETANERCEPT PLUSZ DMARD(OK) ÉS AZ ÖNMAGUKBAN ALKALMAZOTT DMARD(OK) FENNTARTOTT HATÁSOSSÁGÁNAK ÉRTÉKELÉSÉRE RHEUMATOID ARTHRITISBEN SZENVEDŐ BETEGEKNÉL, AKIK MEGFELELŐEN REAGÁLTAK AZ ETANERCEPT PLUSZ DMARD KEZELÉSRE To compare the maintenance of efficacy of the combination of ETN 50 mg once weekly plus MTX (± other DMARDs) therapy with that of MTX (± other DMARDs) at Week 52 in subjects with moderately to severel...

• Country None
• organs None
• Specialty None

A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) To characterize the dose response for tanezumab when administered by SC injection at an 8-weekly interval (2 injections) for moderate to severe chronic pain associated with (IC/PBS). To evaluate the...

• Country None
• organs None
• Specialty None

PILOT STUDY OF NOVEL COMBINATION OF MARAVIROC +ATAZANAVIR/RITONAVIR VS ATAZANAVIR/RITONAVIR +EMTRICITABINE/TENOFOVIR FOR THE TREATMENT OF TREATMENT NAÏVE HIV-INFECTED PATIENTS WITH R5 HIV-1 To examine if the combination of maraviroc (SelzentryTM, Celsentri®) and atazanavir/ritonavir is effective for the treatment of treatment-naïve HIV-1 infected subjects as measured by the percentage of...

• Country None
• organs None
• Specialty None

Study to test whether PF-06480605 is safe and improves symptoms in patients with ulcerative colitis - To evaluate the safety and tolerability of PF-06480605 in subjects with moderate to severe UC. - To evaluate the efficacy of PF-06480605 in induction of endoscopic improvement (as assessed by Mayo ...

• Country None
• organs None
• Specialty None

Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® To assess the impact of prophylactic paracetamol or ibuprofen administration on the immunogenicity of 13vPnC as measured by serotype-specific IgG geometric mean concentrations (GMCs) after completio...

• Country None
• organs None
• Specialty None

A Phase I/II Study of Sunitinib in Young Patients with Advanced Gastrointestinal Stromal Tumor To characterize the plasma PK profile of sunitinib and its active metabolite SU012662 in children and young adults with advanced GIST.

• Country None
• organs None
• Specialty None

A clinical trial to determine if the investigational MnB vaccine works the same every time a batch (or lot) of the vaccine is made Co-Primary  To demonstrate that the immune response induced by 3 lots of rLP2086 vaccine are equivalent as measured by serum bactericidal assay using human complement (hSBA) performed with MnB strai...

• Country None
• organs None
• Specialty None

A Study to Determine the Body's Immune Response To a Vaccination for Herpes Zoster In Subjects Who Have Rheumatoid Arthritis and Receive Tofacitinib (CP-690,550) (the drug being tested) or Placebo To evaluate the effect of tofacitinib on varicella-zoster virus (VZV)-specific immunoglobulin responses in subjects with RA on background methotrexate therapy.

• Country None
• organs None
• Specialty None

A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS 1. To compare the efficacy of tofacitinib at doses of 5 mg BID and 10 mg BID versus placebo for the treatment of rheumatological signs and symptoms of PsA, in subjects with active PsA who have had an ...

• Country None
• organs None
• Specialty None